VJHemOnc Podcast

The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated the community on the latest data and hot topics in the treatment and management of hematological malignancies.

The next questions session at SOHO 2020 illuminated important future considerations in many disease areas of hematological oncology as well as unmet needs in these patient populations.

In this podcast, we hear from Sagar Lonial, MD, FACP, of Winship Cancer Institute of Emory University, Atlanta, GA, Srdan Verstovsek, MD, PhD, and Loretta Nastoupil, MD of The University of Texas MD Anderson Cancer Center, Houston, TX, Amer Zeidan, MBBS, of Yale University and Yale Cancer Center, New Haven, CT, and finally John DiPersio, MD, PhD, of Washington University, St. Louis, MO, on the next questions in the treatment of patients with hematological malignancies.

The post SOHO 2020: Next questions in hematological malignancies appeared first on VJHemOnc.

Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more myeloid lineage with largely intact cellular differentiation. Recent advances in the field, such as the detection of new driver mutations and a better understanding of the molecular pathogenesis of MPNs, have revolutionized the diagnosis, classification and treatment of these hematological malignancies.

The First Texas MPN Workshop brought together medical experts in the field of MPNs to discuss the latest research and therapy options in development for MPNs. In this podcast, Ruben Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the evolving management of MPNs, including learnings following COVID-19, mutations and molecular definitions of disease, interferon-based therapies, clinical trial updates and takeaways from the 2020 Texas MPN Workshop.

The post The MPN Sessions: pathobiology, therapeutic strategies & clinical trials appeared first on VJHemOnc.

Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported in the US in 2020. With the identification of recurrent mutations and the development of novel agents, stratification has allowed for improvements in patient outcomes. In this podcast, Thomas Cluzeau, MD, PhD, of the Central University Hospital of Nice, Nice, France, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discuss key updates in the AML field presented at EHA 2020.

The post Latest AML therapies: novel preparations and first in class agents appeared first on VJHemOnc.

Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin lymphoma which is the 7th most common cancer type in the US and UK, and conversely, Hodgkin lymphoma which constitutes 0.5-1% of all cancers reported in the US and UK. Treatment strategies depend on the type of lymphoma, as well as location and staging. Recent treatment developments include novel chemotherapy agents and immunotherapies including CAR T-cells and antibody-drug conjugates. In this podcast, Wendy Osborne, of Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Peter Borchmann, from the University Hospital Cologne, Cologne, Germany, and Caron Jacobson, of the Dana-Farber Cancer Institute, Boston, MA, discuss updates in the lymphoma field presented at this year’s virtual meeting.

The post Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells appeared first on VJHemOnc.

Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of minimal residual disease (MRD) in disease monitoring. In this podcast, Lydia Scarfò, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.

The post CLL: MRD and first-in class agents appeared first on VJHemOnc.